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Patients with scleroderma (systemic sclerosis-SSc) frequently develop an interstitial lung disease. The role of 
lymphocytes in fibrosing alveolitis preceding lung fibrosis has been established. The purpose of this work was to 
evaluate cell profiles and lymphocyte phenotypes in the bronchoalveolar lavage (BAL) fluid and to correlate them 
with depression in lung function tests detected by depletion of diffusing capacity (DLCO). 
BAL was carried out in 25 untreated, non-smoking patients suffering from diffuse scleroderma and in 12 healthy 
non-smoking volunteers. For the analysis of lymphocyte sub-sets flow cytometry and monoclonal antibodies were 
used. The following cell sub-types were counted: T lymphocytes, B lymphocytes, helper lymphocytes, suppressor/ 
cytotoxic lymphocytes, natural killer cells, cytotoxic T lymphocytes and activated T lymphocytes. 
The total cell count was higher in the group of patients with mild and moderate impairment in DLCO. The 
percentage of lymphocytes was greater in patients with DLCO lower than 65% of the predicted value since 
neutrophilia was found in patients with severe DLCO depletion, i.e. significant when compared with healthy subjects. 
The proportions of suppressor/cytotoxic lymphocytes and of activated T lymphocytes were higher in patients than 
in controls. The statistical analysis revealed significant differences between patients with moderate and mild changes 
in DLCO and the healthy volunteers. A decreased helper/suppressor ratio was noticed in these patients. 
We concluded that the BALF lymphocyte phenotype analysis may reflect the features of alveolitis in patients with 
ssc. 
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Introduction 
Scleroderma (systemic sclerosis-SSc) is a multisystem dis- 
order. Fibrosis of the pulmonary parenchyma is a serious 
complication and has been found in about 80% of patients 
with SSc (1). The fibrotic process is closely linked to an 
inflammatory reaction known as fibrosing alveolitis (2). The 
role of lymphocytes in the pathogenesis of this process in a 
sclerotic lung has been well documented by microscopic 
studies (3-5). Immunosuppressive therapy may be effective 
(6,7) so that early diagnosis of lung involvement in SSc is 
very important. 
We have used bronchoalveolar lavage (BAL) to analyse 
lung cell profiles in patients with systemic sclerosis and in 
healthy non-smoking volunteers. The value of this method 
in patients suffering from SSc has generally been recognized 
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(g-10). In our study BAL was performed in patients with 
minimal lung involvement, thereby this examination was 
well tolerated (9). In the BAL fluid (BALF) cells analysis, 
typical signs of fibrosing alveolitis such as a high total cell 
count, lymphocytosis and low CD4+:CD8+ cells ratio, 
resulting from an elevated CD8+ lymphocyte percentage, 
were observed in patients with various stages of lung 
involvement (9,11,12). The diffusing capacity for carbon 
monoxide (DLCO) has been found to be the most sensitive 
physiological parameter for the early lung changes in the 
course of fibrosing alveolitis (4,13,14). The aim of this part 
of our study was to find a correlation between DLCO 
depression and any possible changes in the BALF, 
particularly those in lymphocyte sub-populations. 
Methods 
SUBJECTS 
The group of patients consisting of 25 subjects (23 women 
and two men) met the American Rheumatism Association 
preliminary criteria for the diagnosis of scleroderma (15). 
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TABLE 1. Results of lung function tests in patients with systemic sclerosis 
Number 
Per cent predicted 
(mean) 
VC -=70% N 6125 (24%) 85 It 22 
FEV, ~70% N 6/25 (24%) 79* 18 
FEV, %VC ~70% N 3/25 (12%) 8Oi 11 
VC 170% N and FEV, ~70% N 3125 (12%) 
TGV > 120% N 3/25 (12%) 104 It 17 
DLCO 61 i 16 
DLCO ~50% N 7/25 (28%) 41 zk 7.5 
DLCO 50-65% N lo/25 (40%) 60 f 3.5 
DLCO >65% N 8125 (32%) 77* 13 
DLCO ~50% and VC ~70% 4/25 (16%) 
VC, vital capacity; FEV,, forced expiratory volume; TGV, thoracic gas volume; DLCO, diffusing 
capacity for carbon monoxide; N, normal values for sex, age and height. 
The diagnosis was established at the Dermatology 
Department, Warsaw Medical School. All patients pre- 
sented clinical symptoms of diffuse scleroderma. In 15 
(60%) of them autoantibodies specific to scleroderma 
TOP0 I were positive. The patients ranged in age from 28 
to 74 years (mean 48 years). The mean duration of the 
disease from the first signs of Raynaud’s phenomenon was 
8 years (from 1 to 17 years). Smokers were excluded 
because abnormalities in the lavage fluid have been associ- 
ated with cigarette smoke inhalation (16). The patients did 
not receive immunosuppressive therapy for at least 2 
months prior to and at the time of lavage. All SSc patients 
underwent clinical evaluation, chest radiography and pul- 
monary function tests before the BAL examination at the 
Department of Pneumonology. Vital capacity (VC) and 
forced expiratory volume (FEV,) were determined using a 
Jaeger spirometer. Lung diffusion capacity was measured 
by steady-state method (DLCOSS). In short: for 2min 
patients breathe a mixture containing O. l-0.2% CO; for the 
next 2 min every 30 s CO concentration in exhaled air and 
in end-tidal 100-200 ml was measured. The minute ventila- 
tion (MV) and CO concentration in inhaled, exhaled and 
end-tidal mixture were calculated. These values enabled us 
to calculate DLCO (DLCO=V/P~ where V indicates CO 
volume diffused from alveolar to capillary blood and Pa 
indicates alveolar CO partial pressure). The predicted 
values for each subject based on sex, age and height were 
obtained from standard tables (17). The patients were 
divided in relation to the DLCO impairment as mild, 
moderate and severe if percentages predicted were higher 
than 65%, 50-65% and less than 50% respectively [(18) 
modified]. The results of pulmonary function tests are 
summarized in Table 1. 
In addition to the group of patients we also evaluated 12 
normal healthy non-smoking volunteers: six women and six 
men, aged 23-66 years (mean age 35 years). 
All patients and normal controls were instructed about 
the risk of the study and gave their informed consent. The 
study was approved by the Ethics Committee of Warsaw 
Medical School. 
METHODS 
Bvonchoalveolav lavage 
The patients and controls underwent BAL after pre- 
medication with atropine and under lidocaine upper res- 
piratory tract anaesthesia. After tracheobronchial tree 
examination the bronchofibroscope was wedged in a sub- 
segment of the right middle lobe. A 200-ml sterile saline 
lavage was performed by sequential instillation of 50-ml 
aliquots, which were subsequently immediately removed 
(19). 
Analysis of BALF cells 
The BAL fluid was filtered through two layers of surgical 
gauze, and the volume of the removed fluid was measured. 
The volume of the recovery fluid larger than 50% was 
regarded as being of diagnostic value. The fluid was centri- 
fuged at 4°C at 300 g for 10 min. Cell viability was deter- 
mined by trypan blue dye exclusion. The total cell count 
and a differential count was performed on smears stained 
with the May-Grunwald-Giemsa (MGG) (300 cells from 
each sample were counted) (19). 
For flow cytometry, the samples of cell suspension (mean 
lo6 cells ml- ‘) were incubated with a mixture of two 
appropriate antibodies at 4°C for 30 min in the dark, 6 ~1 of 
mixture of antibodies being added to 50,ul of the cell 
suspension. Then the cells were washed twice with PBS and 
resuspended in PBS containing 0.5% formaldehyde. For 
double colour analysis the antibodies were conjugated with 
Auorescein isothiocyanate (FITC) or phycoerythrine (PE). 
The antibodies recognizing the following antigens were 
used in pairs: CD45 (FITC)/CD14 (PE), CD3 (FITC)/ 
CD19 (PE), CD4 (FITC)/CD8 (PE), CD3 (FITC)/HLADR 
(PE), CD3 (FITC)/CD56 (PE) and CD16 (PE) (all from 
Becton-Dickinson) and CD25 (FITC)/CD3 (PE) (from 
Dako). Antibodies anti- CD16 and CD56 conjugated with 
phycoerythrine were used together. In each analysis, cells 
stained by FITC- and PE-conjugated isotype mouse-IgG 
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FIG. 1. Differences in the total cell count in the BALF 
from patients with severe, moderate and mild impairment 
in diffusing capacity (DLCO) in SSc patients and healthy 
subjects. (a), Alveolar macrophages; (B), neutrophils; 
(B), lymphocytes. 
8.16 
were employed as negative control. Flow cytometric analy- 
ses were processed by Simul SET software in a FAC Strac 
cytometer (Becton-Dickinson). Eight to 10 x lo4 cells from 
each sample were counted and lymphocyte population were 
selected based on side scatter and expression of CD45 
antigen. The data were analysed using a PC Lysys pro- 
gramme (Becton-Dickinson). For data comparison the 
CD4 + :CDS +, CD4+ :CD3 + and CDS + :CD3 + ratios 
were counted (20). 
Statistical analysis 
A non-parametric analysis was used to make group com- 
parisons of data since BAL cellularity was not distributed 
normally. Median and 0.25-0.75 percentile values were 
used. The Mann-Whitney U-test was applied for the com- 
parisons of the groups (21), P-value CO.05 being regarded 
as significant. The relationship between the proportion of 
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lymphocyte subtypes and the DLCO was tested by the 
Spearman correlation test. 
Results 
LAVAGE FLUID AND CELLULARITY 
The mean recovery volume of the fluid was 130 ml. The 
median of the total cell count in the BALF from patients 
was 7.6 x 106, which was higher than that in healthy 
persons [3.22 x lo6 (P<O.OS)J. Patients with moderate and 
mild DLCO changes had a greater total cell count (PcO.01 
in comparison with healthy persons) which is shown in 
Fig. 1. The proportion of lymphocytes and neutrophils in 
the lavage from patients differed significantly from the 
lavage from normal persons (Table 2). We have found an 
increased proportion of lymphocytes in the BALF in 
patients with severe and moderate impairment of DLCO 
than in the control group (P<O.O5). The difference found in 
the percentage of neutrophils was significant in patients 
with severe DLCO depletion when compared with healthy 
persons (P<O.O5). As shown in Fig. 1 total lymphocytes 
count was also higher in patients with depletion of DLCO 
<65%. The total count of the alveolar macrophages was 
higher in the group of patients, but the analysis of these 
cells was not the subject of the study. 
LYMPHOCYTE PHENOTYPING 
The median percentages of lymphocytes sub-sets in the 
BALF from patients with different changes in DLCO and in 
healthy persons are summarized in Table 3. The median 
proportion of T lymphocytes CD3+ in the BALF in 
patients and controls did not differ significantly. The 
number of B lymphocytes CD19 + in the BALF from 
patients was higher but the difference with the control 
group was not significant. 
Patients suffering from SSc had a greater proportion of 
cytotoxic/suppressor CD8 + lymphocytes and an increased 
CDs+ to CD3+ lymphocyte ratio. The difference was 
TABLE 2. Differential cell profiles obtained with BAL in healthy persons and in patients suffering 
from SSc (smears stained with May-Grunwald-Giemsa) 
Patients n = 25 
Cells 
Healthy subjects DLCO <50% DLCO 50-65% DLCO 165% 
i2=12 n=7 n= 10 n=8 
Lymphocytes (%) 
Macrophages (%) 
Neutrophils (%) 
(8911.5) (lZ0) 
25.5” 
(S-30) (7.:021-5) 
89.5 70” 84.5 
(84-91) (65-79) (5Z9) (73-90.5) 
1.5 
(0.5-2) (24;) (OL5) 
Median values and lower-upper quartile in brackets. 
*P<O.O5 Mann-Whitney test vs control group. 
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TABLE 3. Results of BALF lymphocyte phenotyping in patients with severe (<50% predicted), 
moderate (50-65%) and mild (>65%) impairment in the diffusing capacity for carbon monoxide 
(DLCO) and in healthy subjects 
Patients (n=25) 
Lymphocyte sub-set 
Healthy DLCO -30% DLCO 50-65% DLCO >65% 
(n= 12) I (n=7) II (n= 10) III (n = 8) 
CD3+ 
(T lymphocytes) 
CD19+ 
(B lymphocytes) 
CD4+ 
(helper) 
CDS + 
(cytotoxic/suppressor) 
CD3 - /CD16+CD56+ 
(natural killer) 
CD3 +/HLADR+ 
(activated lymphocytes) 
CD3+/CD16+CD56+ 
(cytotoxic lymphocytes) 
CD25+/CD3+ 
(activated lymphocytes) 
68.0 
(49.5-77.5) 
1.0 
(1.0-1.5) 
41.5 
(25.049.0) 
22.5 
(4.0-27.0) 
4.0 
(3.0-5.5) 
10.5 
(5.0-15.5) 
(2.GO) 
(EO) 
62.0 
(50.0-72.0) 
1.0 
(O-3.0) 
26.0 
(17.0-37.0) 
26.0 
(14.0-29.0) 
(1 ZO) 
13.0 
(5.0-14.5) 
(3.040-O) 
4.0* 
(2.040) 
70.0 
(61.0-84.0) 
3.0 
(1.0-6.0) 
25.0 
(22.0-31.5) 
38.5* 
(26.043.0) 
5.0 
(3.0-5.5) 
16.0 
(X.0-18.0) 
(3.04_05-0) 
(l.cz-0) 
65.0 
(60.0-69.5) 
1.0 
(O-2.0) 
28.5 
(18.0-33.0) 
37.5 
(19.542.0) 
5.0 
(2.5-7.0) 
11.0 
(8.0-15.0) 
4.5 
(2.0-6.5) 
4.5” 
(2.0-6.5) 
*P<O.O5 in Mann-Whitney U-test. 
TABLE 4. Ratios of lymphocyte sub-types in the three groups of patients and in healthy volunteers 
Patients (n=25) 
Ratio of lymphocyte 
sub-types 
Healthy 
(n= 12) 
DLCO 150% DLCO 50-65% DLCO >65% 
I (n=7) II (n= 10) III (n=8) 
CD4+:CD3+ 0.63 0.55 0.42” 0.39* 
(0.58-0.72) (0.42-0.64) (0.35-0.62) (0.32-0.48) 
CD8+:CD3+ 0.36 0.42 0.59* 0.54” 
(0.25-0.41) (0.35-0.57) (0.32-0.61) (0.44-0.58) 
CD4+:CD8+ 1.68 1.53 0.68* 0.70” 
(1.21-2.82) (0.89-2.00) (0.51-0.82) (0.59-1.10) 
*P<O.O5 in Mann-Whitney U-test. 
significant in the group with moderate DLCO depletion 
when compared with healthy persons for percentage of 
CD8+ lymphocytes. When the CD8+:CD3+ (T lympho- 
cytes) ratio was compared differences were found for 
groups II and III (Table 4). The proportion of CD4+ 
lymphocytes was lower in BALF from patients, but only 
the CD4+:CD3+ ratios differed significantly when BALF 
from healthy subjects were compared with BALF from 
patients with moderate and mild DLCO impairment 
(Table 4). The CD4+:CD8+ ratios were decreased in 
BALF from patients in the groups with moderate and 
mild DLCO impairment when compared with the 
controls, the differences being significant (P<O.O5). There 
were higher proportions of activated T lymphocytes with 
HLA DR as well as CD25 antigen expressions in the 
BALF from patients and they were significant for the 
CD25 + :CD3 + lymphocyte percentage between the group 
with mild DLCO depletion and the controls. Interestingly, 
the proportion of NK cells was significantly lower in the 
BALF from patients with severe DLCO depletion. For 
cytotoxic CD 16 + /CD56 + T lymphocytes no significant 
differences were found, though there were higher propor- 
tions of these cells in patients with moderate and mild 
changes in DLCO. 
The proportion of lymphocyte sub-types did not corre- 
late with the depletion in either VC or FEV, nor in 
both. There was no significant correlation between the 
lymphocyte phenotype and the value of DLCO. 
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Discussion 
Lung fibrosis is a common and most serious complication 
in more than 50% of patients with scleroderma. It has been 
well documented that single-site lavage is an acceptable 
method to assess pulmonary inflammation. The aim of our 
study was to determine if the analysis of cell profiles and 
lymphocyte phenotyping in the BALF may be useful in the 
detection of the early stage of the lung disease. We have 
performed BAL in patients with different durations of 
the disease. Previous studies have observed that duration of 
SSc symptoms does not correlate with severity of internal 
organ involvement (12,22). In our previous study we did 
not find any correlation between BALF findings and the 
duration of SSc symptoms (9). Most of our patients did not 
reveal typical features of advanced lung fibrosis apart from 
DLCO depletion. We have found typical clinical signs of 
lung fibrosis in two patients with severe DLCO depletion. 
There were typical radiological features in five patients. 
Only six patients revealed VC depletion and in three 
subjects this was caused by obturation of the bronchial tree. 
Bronchial obturation has been found previously to be a 
feature of lung involvement in the course of scleroderma by 
Kane (23) and Owens (24). The next four patients had 
reduction in both VC and DLCO. The diffusing capacity 
ranged from 32% to 80% of the predicted value in patients. 
In most patients (76%) it was an isolated change. In 
Owens’s study, isolated DLCO reduction was observed in 26 
out of 80 subjects (24), and in Kane’s it was found in 31% 
of patients with diffuse SSc (23). There are only few studies 
in which BALF changes in the early stages of alveolitis have 
been investigated (12,22,25). Since the depletion of DLCO 
to about 50% of the predicted value results from the fibrosis 
of the alveolar wall, active alveolitis with lesser DLCO 
impairment may reflect a reversible process in the alveolar 
lumen (25-27). In his recent study Wells pointed out the 
role of measuring DLCO (28). We have compared the 
results of BALF analysis in three groups of patients with 
three degrees of DLCO reduction and with healthy volun- 
teers, smokers and infected persons being excluded. The 
BAL procedures, mean volumes of the recovered fluid and 
cell viability were comparable in all subjects and controls. 
In the BALF analysis, the main change was an increase in 
the BALF total cell count in patients as compared with 
controls, especially in patients with moderate impairment 
of DLCO. This is a common feature of alveolitis and in 
patients with collagen-vascular disease it is regarded as a 
sign of active lung disease. In this study, the total cell count 
normalized in patients with DLCO ~50% and restrictive 
changes. As also noted by Owens, the recent stage of lung 
fibrosis is characterized by elevated cellularity (12). The 
most important finding in fibrosing alveolitis may be the 
greater proportion of lymphocytes and/or neutrophils 
(7,22,25,29). Data differ from study to study. Interestingly, 
we noticed the greatest proportion of lymphocytes in SSc 
patients with moderate and severe impairment of DLCO 
when compared with healthy subjects. The total number of 
these cells was also higher in these two groups. In the whole 
group of patients we noticed a higher percentage of neu- 
trophils: from 1 to 24% and there were no significant 
differences between these three groups of patients. The 
mean proportion of neutrophils was higher and differed 
significantly between patients with severe DLCO reduction 
and controls. Wells has found neutrophilia accompanying 
extensive changes in lung CT (30). In our observation, 
lymphocytosis as well as neutrophilia are the features of 
lung involvement with advanced changes in DLCO. 
The role of suppressor/cytotoxic lymphocytes with CD8 
antigen expression in the pathogenesis of fibrosing alveolitis 
in scleroderma has been well documented (9,3 1,32). In our 
studies, the increased proportion of these cells was appre- 
ciable in patients with moderate and mild changes in the 
diffusing capacity as well in the total group of patients as 
compared with healthy persons. Owens (12) and Frigieri 
(11) have observed a greater proportion of CD8 + cells in 
patients with SSc. Trentin has provided an explanation for 
the participation of CD8+ lymphocytes in alveolitis in 
hypersensitivity pneumonitis (HP) (33). His suggestion was 
that the increased number of CDX+ cells resulting from 
long-term activation and stimulation by an unknown agent 
may be real in the pathogenesis of alveolitis in scleroderma. 
The CD8+ cells lung compartmentalization was observed 
(34): because the analysis of blood lymphocytes led to 
different results: elevated percentage of CD4+ cells with a 
decreased proportion of CD8 + lymphocytes (35). 
In this study we have found a greater proportion of 
cytotoxic lymphocytes with expression CD3, CD16 and 
CD56 antigens in some patients with minimal changes in 
DLCO. It is known that the proportion of cytotoxic lym- 
phocytes is higher than in the blood (32) but the role of 
cytotoxity requires further investigation (34). 
One of the most important features of alveolitis is a 
marked participation of activated lymphocytes (3,36). The 
proportion of the HLA DR+ lymphocytes T in the BALF 
in patients did not differ significantly when compared with 
the control group. However, in patients with moderate 
DLCO depletion the mean proportion of HLA DR+ T 
lymphocytes was highest. The proportion of CD25+ lym- 
phocytes in the lung is generally low (32,37). In our study, 
there was a relationship between percentage of lymphocytes 
CD25+/CD3+ and the value of the diffusing capacity 
(DLCO): in patients with a mild degree of DLCO depletion 
the percentage of these cells was higher. Our observations 
correlate with Haslam’s findings in lung biopsies: that a 
small number of lymphocytes with 11-2 receptors were 
identified in the sclerotic lungs (3). 
In conclusion, a greater total number of cells, a high 
proportion of CD8 + lymphocytes with a decreased CD4 + : 
CD8-t ratio and a high proportion of activated T lym- 
phocytes CD3+/CD25+ in the BALF may be observed in 
patients with SSc without clinical signs of lung fibrosis and 
with isolated mild or moderate DLCO impairment. 
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